Your browser doesn't support javascript.
loading
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
Ogdie, Alexis; Walsh, Jessica A; Chakravarty, Soumya D; Peterson, Steven; Lo, Kim Hung; Kim, Lilianne; Li, Nan; Hsia, Elizabeth C; Chan, Eric K H; Kavanaugh, Arthur; Husni, M Elaine.
Afiliação
  • Ogdie A; University of Pennsylvania, 3400 Spruce St, White Building, Room 5023, Philadelphia, PA, 19104, USA. alexis.ogdie@uphs.upenn.edu.
  • Walsh JA; University of Utah, George E. Wahlen Veterans Affairs, Salt Lake City, UT, USA.
  • Chakravarty SD; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Peterson S; Drexel University College of Medicine, Philadelphia, PA, USA.
  • Lo KH; Janssen Global Services, LLC, Horsham, PA, USA.
  • Kim L; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Li N; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Hsia EC; Janssen Global Services, LLC, Raritan, NJ, USA.
  • Chan EKH; University of Pennsylvania, 3400 Spruce St, White Building, Room 5023, Philadelphia, PA, 19104, USA.
  • Kavanaugh A; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Husni ME; Janssen Global Services, LLC, Raritan, NJ, USA.
Clin Rheumatol ; 40(9): 3667-3677, 2021 Sep.
Article em En | MEDLINE | ID: mdl-33655380
INTRODUCTION/OBJECTIVES: To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA). METHODS: Patients were randomized to IV golimumab 2 mg/kg (n=241) at Weeks 0, 4, then every 8 weeks (q8w) through Week 52 or placebo (n=239) at Weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at Weeks 24, 28, then q8w through Week 52. Change from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ) was assessed. Relationships between these outcomes and disease activity and patient functional capability were evaluated post hoc. RESULTS: At Week 8, change from baseline in EQ-5D-5L index (0.14 vs 0.04), EQ-VAS (17.16 vs 3.69), daily productivity VAS (-2.91 vs -0.71), and WLQ productivity loss score (-2.92 vs -0.78) was greater in the golimumab group versus the placebo group, respectively. At Week 52, change from baseline was similar in the golimumab and placebo-crossover groups (EQ-5D-5L index: 0.17 and 0.15; EQ-VAS: 21.61 and 20.84; daily productivity VAS: -2.89 and -3.31; WLQ productivity loss: -4.49 and -3.28, respectively). HRQoL and productivity were generally associated with disease activity and functional capability, with continued association from Week 8 through Week 52. CONCLUSION: IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability. Key Points • In patients with active psoriatic arthritis (PsA), intravenous (IV) golimumab improved health-related quality of life (HRQoL) and productivity as early as 8 weeks and maintained improvement through 1 year • Improvements in HRQoL and productivity outcomes in patients with PsA treated with IV golimumab were associated with improvements in disease activity and patient functional capability outcomes • IV golimumab is an effective treatment option for PsA that can mitigate the negative effects of the disease on HRQoL and productivity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Artrite Psoriásica Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Artrite Psoriásica Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article